Trial · NCT02958865
Participant flow96
How many started, completed or left each group, period by period.
21 to 40 of 96
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Induction Period (Day 1 to Week 8) | COMPLETED | PF-06700841 10 mg (Induction) | 45 | |
| Induction Period (Day 1 to Week 8) | COMPLETED | PF-06700841 30 mg (Induction) | 43 | |
| Induction Period (Day 1 to Week 8) | COMPLETED | PF-06700841 60 mg (Induction) | 44 | |
| Induction Period (Day 1 to Week 8) | COMPLETED | PF-06651600 200 mg -> PF-06651600 50 mg | 0 | |
| Induction Period (Day 1 to Week 8) | COMPLETED | PF-06651600 70 mg -> PF-06651600 50 mg | 0 | |
| Induction Period (Day 1 to Week 8) | COMPLETED | PF-06651600 20 mg -> PF-06651600 50 mg | 0 | |
| Induction Period (Day 1 to Week 8) | COMPLETED | Placebo -> PF-06651600 50 mg | 0 | |
| Induction Period (Day 1 to Week 8) | COMPLETED | PF-06700841 60 mg -> PF-06700841 30 mg | 0 | |
| Induction Period (Day 1 to Week 8) | COMPLETED | PF-06700841 30 mg -> PF-06700841 30 mg | 0 | |
| Induction Period (Day 1 to Week 8) | COMPLETED | PF-06700841 10 mg -> PF-06700841 30 mg | 0 | |
| Induction Period (Day 1 to Week 8) | COMPLETED | Placebo -> PF-06700841 30 mg | 0 | |
| Induction Period (Day 1 to Week 8) | COMPLETED | Pooling Placebo During Chronic | 0 | |
| Induction Period (Day 1 to Week 8) | NOT COMPLETED | Placebo (Induction) | 4 | |
| Induction Period (Day 1 to Week 8) | NOT COMPLETED | PF-06651600 20 mg (Induction) | 7 | |
| Induction Period (Day 1 to Week 8) | NOT COMPLETED | PF-06651600 70 mg (Induction) | 6 | |
| Induction Period (Day 1 to Week 8) | NOT COMPLETED | PF-06651600 200 mg (Induction) | 9 | |
| Induction Period (Day 1 to Week 8) | NOT COMPLETED | PF-06700841 10 mg (Induction) | 3 | |
| Induction Period (Day 1 to Week 8) | NOT COMPLETED | PF-06700841 30 mg (Induction) | 4 | |
| Induction Period (Day 1 to Week 8) | NOT COMPLETED | PF-06700841 60 mg (Induction) | 3 | |
| Induction Period (Day 1 to Week 8) | NOT COMPLETED | PF-06651600 200 mg -> PF-06651600 50 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02958865/flow?page=2